Patients with Advanced Ovarian Cancer Seen to Benefit from Oral Therapy in Phase 2 Trial

Patients with Advanced Ovarian Cancer Seen to Benefit from Oral Therapy in Phase 2 Trial
Ovarian cancer patients who are refractory to platinum-based chemotherapy may significantly benefit from the investigative treatment selinexor, according to the results of a Phase 2 clinical trial recently presented at the European Society for Medical Oncology (ESMO) 2016 Congress, held in Copenhagen. The trial also showed promising response rates in patients with endometrial cancer who had received at least one prior line of chemotherapy, but those with cervical cancer did not benefit as much as patients in the other two groups. Selinexor, being developed by Karyopharm Therapeutics, is a first-in-class oral inhibitor of the nuclear export protein XPO1. Some cancer cells thrive by getting rid of tumor suppressor proteins (proteins that protect the cells from turning cancerous). By preventing these proteins from leaving the nucleus, selinexor induces the death of cancer cells, while sparing healthy cells. The randomized, open-label Phase 2 study (NCT02025985), co-led by Ignace B. Vergote, MD, PhD, head of the department of obstetrics and gynecology, and gynecologic oncology, at Catholic University of Leuven in Belgium, was designed to assess the safety and efficacy of selinexor in patients with advanced gynecologic malignancies, including ovarian, endometrial, and cervical cancers. The study enrolled 66 ovarian cancer patients (median age 62) who were refractory to platinum-based chemotherapy, as well as 23 patients with endometrial cancer (median age 67) and 25 patients with cervical cancer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *